A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Dovitinib (Primary) ; Dovitinib
  • Indications Colon cancer; Lung cancer; Rectal cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Apr 2014 Results presented at the 105th Annual Meeting of the American Association for Cancer Research.
    • 18 Oct 2013 Planned end date changed from 1 Jan 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top